Good morning to you all. Please find enclosed a summary of the breaking small-cap and micro-cap financial news we highlighted on AGORACOM Small Cap TV this morning. It’s March 7th , 2012, and we’ve found 3 great press releases to report on at the open. Another great day for small-cap and micro-cap financial news. To watch the show live every morning at 9:30 AM, visit our front page.

Golden Hope Intersects 3.08 g/t Au Over 25 Metres and 2.01 g/t Au Over 32 Metres at Bellechasse-Timmins, Quebec

Golden Hope Mines (TSX VENTURE: GNH)( Pink Sheets: GOLHF) –

Golden Hope Mines Limited is pleased to announce further significant results from its 2011 drill campaign in southeastern, Quebec. The company is pleased to present the following highlights from holes BD2011-174, 175, 176 and 177.

About Golden Hope Mines Limited:

Golden Hope Mines Limited is a mineral exploration company that seeks to grow shareholder value through the acquisition, exploration and development of potentially large-scale gold and base metal projects suitable for underground and/or open-pit mining. The company's focus is in southeastern Quebec, Canada.

Last: 0.25Range: 0.325-0.10Market Cap: 32.8 Million

Link to hub

Augme Technologies Expects to Report Record Fourth Quarter Revenue of Approximately $5.1 Million

Augme Technologies, Inc. (OTCBB: AUGT) ("Augme®") ("the Company"), a technology and services leader in interactive media marketing that offers the only patented and innovative end-to-end mobile marketing platform, today announced that it expects to report revenue of approximately $5.1 million for the fourth quarter of fiscal 2012 ended February 29, 2012, based on a preliminary review of results. This represents a sequential increase of approximately 15% relative to revenue of $4.43 million in the third quarter ended November 30, 2011.

Revenue for the fourth quarter of fiscal 2011 ended February 28, 2011 did not include results for Hipcricket, Inc. which Augme acquired on August 25, 2011. For that period, the Company reported revenue of $0.96 million.

Total backlog, or the dollar value of signed contracts, was approximately $15.6 million at February 29, 2012 compared to $13.1 million at November 30, 2011, the end of the third fiscal quarter, representing a 19% increase.

Augme focus on adding new customers while increasing revenue per customer through deeper penetration of existing customers' brand portfolios produced a $1.2 million, or 23%, increase in new order bookings to approximately $6.5 million for the fourth quarter.

About Augme Technologies, Inc.

Augme® Technologies, Inc. (OTCBB: AUGT) provides strategic services and mobile marketing technology to leading consumer and healthcare brands. Selling its products and services under the Hipcricket brand, its platform, has provided measurable successes across an industry-leading 150,000+ campaigns for such clients as Macy's, MillerCoors, Nestle, and Clear Channel. Augme's offerings allow marketers, brands, and agencies to plan, create, test, deploy, and track mobile marketing programs across every mobile channel, including SMS, MMS, 2D/QR codes, mobile websites, advertising networks, social media and branded apps.

Last Trade: 1.89 52 Week: 4.66 – 1.17 Market Cap: 178.25 Million

Transgenomic Reports Fiscal Year 2011 Financial Results

Transgenomic, Inc. (OTCBB: TBIO) today reported financial results for the year ended December 31, 2011 and provided a business update.

Fourth Quarter and Fiscal Year Financial Results

Total revenue for the fourth quarter 2011 was $8.6 million, an increase of 68 percent compared with $5.1 million for the same period of 2010. Revenues for the fourth quarter of 2011 included $4.6 million in sales related to the Clinical Labs business, $0.5 million in revenue related to the Pharmacogenomics Services Unit (“Pharma” which supports Clinical Trials) and $3.5 million in revenue related to the Diagnostic Tools unit.

For the year ended December 31, 2011, revenues were $32.0 million, an increase of 59 percent compared with $20.0 million for the same period of 2010. This included $16.0 million in net sales related to the Clinical Labs, $2.3 million in Pharma revenues and $13.7 million in revenues related to the Diagnostic Tools unit.

Gross profit was $5.3 million, or 62 percent of net sales during the fourth quarter of 2011, compared with gross profit of $2.4 million, or 47 percent of net sales during the comparable period of 2010. Gross profit was $18.4 million, or 58 percent of net sales for 2011, compared with gross profit of $9.8 million, or 49 percent of net sales for 2010.

Net income for the fourth quarter of 2011 was $0.3 million, or $0.00 per share, compared with a net loss of $0.8 million, or $0.02 per share, for the fourth quarter of 2010. The Company reported a net loss for the year ended December 31, 2011 of $9.8 million, or $0.22 per share, compared with a net loss of $3.1 million, or $0.06 per share, for 2010.

Modified EBITDA, which is a non-GAAP measure that Transgenomic views as an appropriate and sound measure of the Company's results, improved to a gain of $615,000 for the fourth quarter of 2011 from a proforma loss of $1.4 million for the same period for 2010. For the year ended December 31, 2011, Modified EBITDA was a gain of $195,000 as compared to a proforma loss of $6.3 million for the same period for 2010.

About Transgenomic

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company has three complementary business divisions: Transgenomic Pharmacogenomic Services is a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development.

Last Trade: 1.35 52 Week: 1.85 – 0.66 Market Cap: 66.66 Million